Drug intelligence / Profile preview

AK104 + oxaliplatin + irinotecan + fluorouracil + leucovorin

Development stage: Unknown
Lead developer: Akeso
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Intravenous

Overview

This is a **combination regimen** consisting of AK104 (cadonilimab), a bispecific monoclonal antibody targeting both Programmed death-1 (PD-1) and Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), together with the chemotherapeutic agents oxaliplatin, irinotecan, fluorouracil (5-FU), and leucovorin. AK104 (cadonilimab) acts through immune checkpoint inhibition, potentiating antitumor immune responses. The regimen leverages the immunomodulatory effects of AK104 alongside the cytotoxic action of platinum-based (oxaliplatin) and topoisomerase inhibitor (irinotecan) chemotherapy, as well as the antimetabolite actions of fluorouracil and leucovorin, to treat advanced gastrointestinal and related solid tumors, including colorectal and gastric cancers[3][5][6]. The combination is currently being investigated in clinical trials as neoadjuvant or first-line therapy settings.

Brand names: cadonilimab
Other names: anti-PD-1/CTLA-4 bispecific antibody + oxaliplatin + irinotecan + fluorouracil + leucovorin

Targets

PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)TOP1 (DNA Topoisomerase I)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)DNA

Beyond the preview

Go deeper on AK104 + oxaliplatin + irinotecan + fluorouracil + leucovorin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AK104 + oxaliplatin + irinotecan + fluorouracil + leucovorin.

Explore the full profile